Vaccine Adverse Reaction Clinical Trial
Official title:
Immunogenicity and Safety of Recombinant Zoster Vaccine in People Living With HIV
The purpose of this study is to compare the immunogenicity and safety of recombinant zoster vaccine according to CD4+ T-cell count and age in people living with HIV, and to provide evidence to guide immunization of people living with HIV.
Status | Recruiting |
Enrollment | 150 |
Est. completion date | March 31, 2026 |
Est. primary completion date | March 31, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility | Inclusion Criteria (for HIV #1, HIV #2) : - 19 years old or older, HIV-1 infected person who have voluntarily agreed to participate in the study. - Have been taking antiviral medications stably for at least one month at the time of screening. - Have a CD4+ T-cell count measured within one month of screening. - Do not have AIDS-defining diseases (excluding oral thrush) or acute/uncontrolled opportunistic infection at the time of enrollment. - Do not have uncontrolled chronic medical conditions other than HIV infection. Inclusion Criteria (for non-HIV) : - 50 years old or older who have voluntarily agreed to participate in the study. - Do not have uncontrolled chronic medical conditions Exclusion Criteria: - Have received any type of zoster vaccine within 1 year. - Have been diagnosed with chickenpox or shingles within 12 months. - Have a history of severe allergy to any of the components of Shingrix vaccine. - Have a acute medical condition at the time of screening. - Unable to be evaluated for adverse events via telephone contact after vaccination. - Pregnant (including those planning to become pregnant) or lactating women. - Those who have received chemotherapy or radiotherapy within 6 months prior to the first vaccine dose. - Chronic administration of immunosuppressive or other immune-modifying drugs within 6 months prior to ther first vaccine dose. - Administration of immunoglobulins, and/or any blood products within 3 months preceding the first dose of study vaccine - Have a medical condition that makes receiving an intramuscular injection medically contraindicated. - Have a disease or condition that may affect the immunogenicity or safety of the vaccine. - Receiving any other vaccine within 14 days prior to and 14 days after receiving the study vaccine. - Participate in a clinical trial that involves other investigational product or device during the course of the study. - Any other person who, in the opinion of the investigator, is unsuitable for immune response assessment. |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | National Medical Center | Seoul | |
Korea, Republic of | Seoul National University Hospital | Seoul |
Lead Sponsor | Collaborator |
---|---|
Seoul National University Hospital | National Medical Center, Seoul, SMG-SNU Boramae Medical Center |
Korea, Republic of,
Berkowitz EM, Moyle G, Stellbrink HJ, Schurmann D, Kegg S, Stoll M, El Idrissi M, Oostvogels L, Heineman TC; Zoster-015 HZ/su Study Group. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2015 Apr 15;211(8):1279-87. doi: 10.1093/infdis/jiu606. Epub 2014 Nov 3. — View Citation
Buchbinder SP, Katz MH, Hessol NA, Liu JY, O'Malley PM, Underwood R, Holmberg SD. Herpes zoster and human immunodeficiency virus infection. J Infect Dis. 1992 Nov;166(5):1153-6. doi: 10.1093/infdis/166.5.1153. — View Citation
Centers for Disease Control and Prevention (CDC). Revised surveillance case definition for HIV infection--United States, 2014. MMWR Recomm Rep. 2014 Apr 11;63(RR-03):1-10. — View Citation
Domingo P, Torres OH, Ris J, Vazquez G. Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection. Am J Med. 2001 Jun 1;110(8):605-9. doi: 10.1016/s0002-9343(01)00703-3. — View Citation
Erdmann NB, Prentice HA, Bansal A, Wiener HW, Burkholder G, Shrestha S, Tang J. Herpes Zoster in Persons Living with HIV-1 Infection: Viremia and Immunological Defects Are Strong Risk Factors in the Era of Combination Antiretroviral Therapy. Front Public Health. 2018 Mar 12;6:70. doi: 10.3389/fpubh.2018.00070. eCollection 2018. — View Citation
Gebo KA, Kalyani R, Moore RD, Polydefkis MJ. The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):169-74. doi: 10.1097/01.qai.0000178408.62675.b0. — View Citation
Grabar S, Tattevin P, Selinger-Leneman H, de La Blanchardiere A, de Truchis P, Rabaud C, Rey D, Daneluzzi V, Ferret S, Lascaux AS, Hanslik T, Costagliola D, Launay O; French Hospital Database on HIV (FHDH-ANRS CO4 Cohort). Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort. Clin Infect Dis. 2015 Apr 15;60(8):1269-77. doi: 10.1093/cid/ciu1161. Epub 2015 Jan 18. — View Citation
Harbecke R, Cohen JI, Oxman MN. Herpes Zoster Vaccines. J Infect Dis. 2021 Sep 30;224(12 Suppl 2):S429-S442. doi: 10.1093/infdis/jiab387. — View Citation
Kim YJ, Woo JH, Kim MJ, Park DW, Song JY, Kim SW, Choi JY, Kim JM, Han SH, Lee JS, Choi BY, Lee JS, Kim SS, Kee MK, Kang MW, Kim SI. Opportunistic diseases among HIV-infected patients: a multicenter-nationwide Korean HIV/AIDS cohort study, 2006 to 2013. Korean J Intern Med. 2016 Sep;31(5):953-60. doi: 10.3904/kjim.2014.322. Epub 2016 Apr 27. — View Citation
Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Available at https://clinicalinfo.hiv.gov/en/guidelines/adult-andadolescent-opportunistic-infection. Accessed March 31, 2023
Song JY, Lee JS, Jung HW, Choi HJ, Lee JS, Eom JS, Cheong HJ, Jung MH, Kim WJ. Herpes zoster among HIV-infected patients in the highly active antiretroviral therapy era: Korean HIV cohort study. J Acquir Immune Defic Syndr. 2010 Mar;53(3):417-8. doi: 10.1097/QAI.0b013e3181b1d6dc. No abstract available. — View Citation
Thompson MA, Horberg MA, Agwu AL, Colasanti JA, Jain MK, Short WR, Singh T, Aberg JA. Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2021 Dec 6;73(11):e3572-e3605. doi: 10.1093/cid/ciaa1391. Erratum In: Clin Infect Dis. 2021 Dec 08;: Clin Infect Dis. 2022 Nov 30;75(11):2052. — View Citation
* Note: There are 12 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Humoral immune response | Defined as a 4-fold or greater increase in anti-VZV antibody concentration from pre-vaccination testing in seropositive subjects and a 4-fold or greater increase in anti-gE antibody concentration from the cutoff in seronegative subjects prior to vaccination. | 1 month, 13 months after 2nd dose | |
Secondary | Cell-mediated immunogenicity | Defined as a 2-fold or greater increase in CD4+ T cells expressing at least two activation markers (i.e. CD40L, IFN-gamma, IL-2 or TNF-alpha) post-vaccination compared to pre-vaccination baseline. | 1 month, 13 months after 2nd dose | |
Secondary | Differences in humoral immune response and cell mediated immunogenecity | Comparison of geometric mean of anti VZV IgG titer and proportions of VZV-specific CD4+ and CD8+ T-cells between HIV#1 and HIV#2 | 1 month, 13 months after 2nd dose | |
Secondary | Grade 3/4 adverse events (AE) | Solicited and unsolicited local and systemic adverse events occurring within 7 days after the first and second dose | Within 7 days (Day 0-6) after the first and second dose. | |
Secondary | Any serious adverse events (SAEs) | Any serious adverse events occurring throughout the study period | Throughout the study period: Day 0~450 or termination, whichever came first | |
Secondary | Increase in HIV Viral Load or decrease in CD4+ T-cell Count | Increase in HIV Viral Load by 0.5 log or more or decrease in CD4+ T-cell Count by 30% or more | 1 month after 2nd dose | |
Secondary | Any AIDS-defining disease | Occurrence of any AIDS defining condition according to the appendix of the "Revised surveillance case definition for HIV infection--United States, 2014" (Centers for Disease Controls and Prevention); | Within 3 months after 2nd dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03966391 -
Effectiveness of CARD for Improving School-Based Immunizations
|
N/A | |
Completed |
NCT04530357 -
Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine
|
Phase 1/Phase 2 | |
Terminated |
NCT03966300 -
Improving the School Vaccination Experience: What CARDs Are You Going to Play?
|
N/A | |
Active, not recruiting |
NCT06286488 -
Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza
|
Phase 4 | |
Recruiting |
NCT05546502 -
Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children
|
Phase 3 | |
Active, not recruiting |
NCT05483725 -
Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients.
|
||
Completed |
NCT03600428 -
Safety of LAIV4 in Children With Asthma
|
Phase 4 | |
Completed |
NCT03400878 -
Comparing Morbidity and Mortality Effects of Two Different Strains of BCG
|
Phase 4 | |
Completed |
NCT05116748 -
COVID19 Vaccine in SOT Adult Recipients
|
||
Not yet recruiting |
NCT05171946 -
Phase-I Study to Evaluate the Safety and Immunogenicity of a Prophylactic pDNA Vaccine Candidate Against COVID-19 in Healthy Adults
|
Phase 1 | |
Recruiting |
NCT05128721 -
Evaluation of Inactivated Vaccine in Healthy Adults Against Coronavirus Disease of 2019 (COVID-19)
|
Phase 1 | |
Withdrawn |
NCT04894682 -
Safety and Long-term Effects of COVID-19 Vaccines in Patients With Pulmonary Tumor
|
||
Not yet recruiting |
NCT05387252 -
Glucoside- and Rutinoside-rich Crude Material for Relieving Side Effects of COVID-19 Vaccines
|
N/A | |
Active, not recruiting |
NCT04801667 -
Evaluate the Impact, Safety, Tolerability and Immunogenicity of the Coronavac Vaccine in Kidney Transplant Recipients
|
Phase 4 | |
Not yet recruiting |
NCT05283902 -
Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly
|
||
Recruiting |
NCT05095844 -
National Vaccine Adverse Event Reporting Survey and Etiology
|
||
Recruiting |
NCT05315856 -
Reactogenicity, Immunogenicity and Inflammatory Response by New COVID-19 Vaccine Platforms
|
||
Recruiting |
NCT05212792 -
Genomics and COVID-19 Vaccine Adverse Events
|
||
Recruiting |
NCT05258708 -
COVID-19 Vaccine Reactogenicity and Immunogenicity
|
||
Not yet recruiting |
NCT05482295 -
Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III)
|
Phase 3 |